批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2023/03/29 |
SUPPL-6(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2023/03/27 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/08/06 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2019/09/23 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2017/01/24 |
SUPPL-1(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2015/11/18 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:NALOXONE HYDROCHLORIDE 剂型/给药途径:SPRAY, METERED;NASAL 规格:4MG/SPRAY 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
208411 |
001 |
NDA |
NARCAN |
NALOXONE HYDROCHLORIDE |
SPRAY, METERED;NASAL |
4MG/SPRAY |
Over-the-counter |
Yes |
Yes |
AB |
2015/11/18
|
EMERGENT |
209522 |
001 |
ANDA |
NALOXONE HYDROCHLORIDE |
NALOXONE HYDROCHLORIDE |
SPRAY, METERED;NASAL |
4MG/SPRAY |
Over-the-counter |
No |
No |
AB |
2019/04/19
|
TEVA PHARMS USA |
211951 |
001 |
ANDA |
NALOXONE HYDROCHLORIDE |
NALOXONE HYDROCHLORIDE |
SPRAY, METERED;NASAL |
4MG/SPRAY |
Over-the-counter |
No |
No |
AB |
2022/06/21
|
PADAGIS ISRAEL |